Last reviewed · How we verify

NCT04181437: Navipharm

Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2

Completed Phase 1 Last updated 1 September 2020
What this trial tests

Phase 1 trial testing NVP-1203-R1 in Healthy in 40 participants. Completed in 29 May 2020.

Timeline
1 May 2020
Primary endpoint
17 May 2020
29 May 2020

Quick facts

Lead sponsorNVP Healthcare
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment40
Start date1 May 2020
Primary completion17 May 2020
Estimated completion29 May 2020
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

NVP Healthcare — full company profile →

Who can join

19 and older, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the pharmacokinetics and safety between NVP-1203-R1 and NVP-1203-R2

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other NVP Healthcare trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04181437.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing